Prostate cancer is the most common male cancer, with around 400,000 new cases every year in Europe. Active Surveillance (AS) is being considered as an alternative treatment strategy for patients with low-risk prostate cancer. Active Surveillance is a treatment strategy that involves close monitoring of patients diagnosed with low-risk prostate cancer. It aims to protect the patient’s Qualitiy of Life by delaying radical treatments such as immediate curative treatment, unless there are changes in the test results which show the condition is getting worse.
Immediate curative treatment involves surgery and radiotherapy that can cause distressing side effects such as incontinence or impotence.
There are ongoing clinical trials for evaluating the use of prostate cancer biomarkers in first void urine samples.